Oxidative stress and aminopeptidases in Parkinson's disease patients with and without treatment

Neurodegenerative Diseases

Volumn 8, Issue 3, 2011, Pages 109-116

  Duran, Raquel ^a   Barrero, Francisco J ^c   Morales, Blas ^c   Luna, Juan D ^b   Ramirez, Manuel ^d   Vives, Francisco ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d UNIVERSITY OF JAÉN   (Spain)

Author keywords

Impairment; Oxidative stress; Parkinson's disease; Protein metabolism

Indexed keywords

ALANINE; AMINOPEPTIDASE; ASPARTIC ACID; CARBIDOPA; CYSTINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTIC ACID; LEVODOPA; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; COLORIMETRY; CONTROLLED STUDY; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME METABOLISM; FEMALE; FLUOROMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN METABOLISM; WESTERN BLOTTING;

AGED; AMINOPEPTIDASES; ANTIPARKINSON AGENTS; CARBIDOPA; CASE-CONTROL STUDIES; FEMALE; HUMANS; LACTATES; LEVODOPA; LIPID PEROXIDES; LIPIDS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 79953294305     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000315404     Document Type: Article

References (43)

1. Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005; 28: 57-87.
2. Levy G: The relationship of Parkinson disease with aging. Arch Neurol 2007; 64: 1242- 1246. (Pubitemid 47403076)
3. Parker WD, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719-723. (Pubitemid 20011004)
4. Nagatsu T, Sawada M: Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes and inflammatory cytokines. Cell Mol Neurobiol 2006; 26: 781- 802.
5. Keeney PM, Xie J, Capaldi RA, Bennett JP: Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 2006; 26: 5256-5264. (Pubitemid 44315308)
6. Koutsilieri E, Scheller C, Grünblatt E, Nara K, Li J, Riederer P: Free radicals in Parkinson's disease. J Neurol 2002; 249(suppl 2):S1- S5.
7. Sayre LM, Perry G, Smith MA: Oxidative stress and neurotoxicity. Chem Res Toxicol 2008; 21: 172-188. (Pubitemid 351219718)
8. Mytilineou C, Han SK, Cohen G: Toxic and protective effects of L -dopa on mesencephalic cell cultures. J Neurochem 1993; 61: 1470- 1478. (Pubitemid 23285107)
9. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonucelli U, Damier P, de Yebenes J, Gershanik O, Guttman M, Grandes F, Hallett M, Hornykiewiez O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vorazi R, Rajput AH, Rascol O, Sampaio C, Stocchi F: Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19: 997-1005. (Pubitemid 39302831)
10. Martignoni E, Blandini F, Godi L, Desideris S, Pacchetti C, Mancini F, Nappi G: Peripheral markers of oxidative stress in Parkinson's disease: the role of levodopa. Free Radic Biol Med 1999; 27: 428-437. (Pubitemid 29395437)
11. Buhmann C, Arlt S, Kontush A, Möller-Bertram T, Sperber S, Oechsner M, Stuerenburg HJ, Beisiegel U: Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. Neurobiol Dis 2004; 15: 160-170. (Pubitemid 38134391)
12. Agil A, Duran R, Barrero F, Morales B, Araazo M, Alba F, Miranda MT, Prieto I, Ramírez M, Vives F: Plasma lipid peroxidation in sporadic Parkinson's disease: role of the L -dopa. J Neurol Sci 2006; 240: 31-36. (Pubitemid 41814950)
13. Prigione A, Begni B, Galbussera A, Beretta S, Brighina L, Garofalo R, Andreoni S, Piolti R, Ferrarese C: Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol Dis 2006; 23: 36-43. (Pubitemid 43903629)
14. Onyango IG: Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochem Res 2008; 33: 589-597. (Pubitemid 351230462)
15. Chung KK, Dawson VL, Dawson TM: The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci 2001; 24(suppl 1):S7-S14.
16. Gil J, Larrinaga G, Maena J, Rodríguez-Puertas R, Irazusta J, Casis L: Regional and subcellular distribution of soluble aminopeptidase in the human and the rat brain: a comparative study. Neuropeptides 2001; 35: 276-284. (Pubitemid 34587510)
17. Matsumoto H, Nagasaku T, Hattori A, Rogi T, Tsuruoka N, Mizutani S, Tsujimoto M: Expression of placental leucine aminopeptidase/ oxytocinase in neuronal cells and its action on neuronal peptides. Eur J Biochem 2001; 268: 3259-3266. (Pubitemid 32823000)
18. Banegas I, Ramírez M, Vives F, Alba F, Segarra AB, Duran R, de Gasparo M, Prieto I: Aminopeptidase activity in the nigrostriatal system and prefrontal cortex of rats with experimental hemiparkinsonism. Horm Metab Res 2005; 37: 1-3
19. Banegas I, Barrero H, Duran R, Morales B, Luna JD, Prieto I, Ramírez M, Alba F, Vives F: Plasma aminopeptidase activities in Parkinson's disease. Horm Metab Res 2006; 38: 758-760. (Pubitemid 44885429)
20. Banegas I, Prieto I, Vives F, Alba F, Duran R, Segarra AB, de Gasparo M, Ramírez M: Plasma aminopeptidase activities in rats after left and right intrastriatal administration of 6-hydroxydopamine. Neuroendocrinology 2004; 80: 219-224. (Pubitemid 40187007)
21. Ahmad S, Ward PE: Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins. J Pharmacol Exp Ther 1990; 252: 643-650. (Pubitemid 20101879)
22. Abhold RH, Sullivan MJ, Wright JW, Harding JW: Binding, degradation and pressor activity of angiotensins II and III alter aminopeptidase inhibition with amastatin and bestatin. J Pharmacol Exp Ther 1987; 242: 957-962. (Pubitemid 17156538)
23. Tsujimoto M, Mizutani S, Adachi H, Kimura H, Nakazato H, Tomoda Y: Identification of human placental leucine aminopeptidase as oxytocinase. Arch Biochem Biophys 1992; 292: 388-392.
24. Thompson MW, Hersh LB: The puromycinsensitive aminopeptidase; in Hooper NM, Lendeckel U (eds): Aminopeptidases in Biology and Disease. New York, Kluwer Academic Plenum, 2004, pp 1-15.
25. Greenfield SA, Shaw SG: Release of acetylcholinesterase and aminopeptidase in vivo following infusion of amphetamine into the substantia nigra. Neuroscience 1982; 7: 2883- 2893. (Pubitemid 13203972)
26. Gelb D, Oliver E, Gilman S: Diagnostic criteria for Parkinson's disease. Arch Neurol 1999; 56: 33-39.
27. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
28. Zhou C, Huang Y, Przedborski S: Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann NY Acad Sci 2008; 1147: 93-104.
29. Hattori N, Wanga M, Takab H, Fujimurab T, Yoritaka A, Kuboa S, Mochizukia H: Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism Relat Disord 2009; 15(suppl 1):S35-S38.
30. Younes-Mhenni S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G: Peripheral blood markers of oxidative stress in Parkinson's disease. Eur Neurol 2007; 58: 78-83. (Pubitemid 47237650)
31. Chen CM, Liu JL, Wu YR, Chen YC, Cheng HS, Cheng ML, Chiu DT: Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiol Dis 2009; 33: 429-435.
32. di Monte D, Tetrud JW, Langston JW: Blood lactate in Parkinson's disease. Ann Neurol 1991; 29: 342-343.
33. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Shapira AH, Jenner P, Marsden CD: Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35: 33-44.
34. Kuda T, Shoji M, Arai H, Kawashima S, Saido TC: Reduction of plasma glutamyl aminopeptidase activity in sporadic Alzheimer's disease. Biochem Biophys Res Commun 1997; 231: 526-530. (Pubitemid 27217544)
35. Saido TC: Alzheimer's disease as proteolytic disorders: anabolism and catabolism of β - amyloid. Neurobiol Aging 1998; 19:S69-S75. (Pubitemid 28178942)
36. Hook V: Protease pathways in peptide neurotransmission and neurodegenerative diseases. Cell Mol Neurobiol 2006; 26: 449-469.
37. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ: A precipitating role for truncated α -syn and the proteasome in α -syn aggregation: implications for pathogenesis of Parkinson's disease. J Biol Chem 2005; 280: 22670-22678. (Pubitemid 40853171)
38. Banegas I, Prieto I, Vives F, Alba F, de Gasparo M, Segarra AB, Hermoso F, Duran R, Ramírez M: Brain aminopeptidases and hypertension. J Renin Angiotensin Aldosterone Syst 2006; 7: 129-134. (Pubitemid 44740946)
39. Ukponmwan OE, Rupreht J, Dzoljic M: An analgesic effect on enkephalinase inhibition is modulated by monoamine oxidase B and REM sleep deprivations. Naunyn Schmiedebergs Arch Pharmacol 1986; 322: 376-379. (Pubitemid 16122206)
40. Sivam SP: Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline. Neuropeptides 1993; 25: 35-45.
41. Waters SM, Konkoy CS, Davis TP: Neuropeptide metabolism in intact, regional brain slices: effect of dopamine agents on substance P, cholecystokinin and Met-enkephalin degradation. J Pharmacol Exp Ther 1995; 274: 783-789.
42. Waters SM, Rounseville MP, Davis TP: Effect of dopaminergic drugs on processing and degradative neuropeptidase mRNA in rat frontal cortex and caudate-putamen. Brain Res 1997; 754: 28-34. (Pubitemid 27170248)
43. Banegas I, Prieto I, Vives F, Alba F, de Gasparo M, Duran R, Luna Jde D, Segarra AB, Hermoso F, Ramírez M: Asymmetrical response of aminopeptidase A and nitric oxide in plasma of normotensive and hypertensive rats with experimental hemiparkinsonism. Neuropharmacology 2009; 56: 573-579.